All In Biotech

Drug Trial Radar · NCT07564141

Study to Assess the Efficacy and Safety of Rina-S With or Without Bevacizumab Compared to Investigator's Choice of Platinum-based Chemotherapy With or Without Bevacizumab as Second-line Treatment in Participants With Recurrent Platinum-sensitive Ovarian Cancer

A Randomized, Open-label, Phase 3 Study of Rina-S ± Bevacizumab Versus Investigator's Choice of Platinum-Based Chemotherapy ± Bevacizumab as 2L Treatment in Participants With Recurrent Platinum-Sensitive Ovarian Cancer

Last checked: Nov 19, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 688 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

688

Planned (sponsor's estimate)

Start

Aug 28, 2026

Primary completion

Dec 2029

Study completion Nov 2031

Sponsor

Lead sponsor
GenmabIndustry
Sponsor type
Industry
First posted
May 4, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This Phase 3 study will be conducted in different countries around the world with up to about 688 participants. The purpose of this study is to evaluate how well Rina-S works against ovarian cancer in combination with or without bevacizumab and how it compares to an investigator's choice of platinum-based chemotherapy with or without bevacizumab. Participants will receive either: * Rina-S monotherapy (by itself), * Rina-S plus bevacizumab, * investigator's choice chemotherapy (by itself) (standard of care), or * investigator's choice chemotherapy plus bevacizumab (standard of care). No participants will be given placebo. Participants will participate in 1 of 2 arms. The treatment duration will be different for every participant. If a participant's cancer stays the same or gets better, and there are not any serious problems, participants can keep getting study treatment for as long as the study is open. Participants will be asked to attend 1 to 3 visits at the study clinic for each cycle (duration of cycle is 3 or 4 weeks, depending on medication received). During visits, there will be various tests (such as blood draws) and procedures (such as recording of heart activity and imaging) to monitor whether the study treatment is safe and effective. The overall study duration (including screening, treatment, and follow-up) will be different for every participant.

Conditions

  • Platinum-Sensitive Ovarian Cancer
  • Ovarian Cancer

Interventions

  • Rina-SBiological

    Intravenous (IV) infusion

  • BevacizumabDrug

    IV infusion

  • CarboplatinDrug

    IV infusion

  • GemcitabineDrug

    IV infusion

  • PaclitaxelDrug

    IV infusion

  • PLDDrug

    IV infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free Survival (PFS) per Response Evaluation Criteria in Solid Tumours (RECIST) v1.1, as Determined by Blinded Independent Central Review (BICR)Time frame: Up to approximately 3 years

Locations

12 sites in 3 countries. Site status is shown where the registry gives one.

  • City of Hope

    Duarte, California · Recruiting

  • Danbury Hospital

    Danbury, Connecticut · Recruiting

  • Compass Oncology - West Cancer Center (Northwest Cancer Specialists, P.C.)

    Tigard, Oregon · Recruiting

  • Alliance Cancer Specialists, PC

    Bensalem, Pennsylvania · Recruiting

  • Utah Cancer Specialists

    South Jordan, Utah · Recruiting

  • West Virginia University

    Morgantown, West Virginia · Recruiting

  • ProHealth Care Inc

    Waukesha, Wisconsin · Recruiting

  • Tampere University Hospital

    Tampere, Pirkanmaa, Finland · Recruiting

  • The Cancer Institute Hospital of JFCR

    Tokyo, Koto City, Japan · Recruiting

  • Niigata Cancer Center Hospital

    Chuo Ku Niigata, Niigata, Japan · Recruiting

  • Tokushima University Hospital

    Tokushima, Tokushima, Japan · Recruiting

  • Yamagata University Hospital

    Yamagata, Yamagata, Japan · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.